Cargando…

See Lung Cancer with an AI

SIMPLE SUMMARY: Lung cancer is the cause of many deaths that could have been avoided if the disease had been detected at an early stage. This is possible thanks to the lung cancer screening (LCS) program with the low-dose computed tomography (LDCT) of the chest. Due to the heavy workload on the heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidzińska, Joanna, Szurowska, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954317/
https://www.ncbi.nlm.nih.gov/pubmed/36831662
http://dx.doi.org/10.3390/cancers15041321
_version_ 1784894091938496512
author Bidzińska, Joanna
Szurowska, Edyta
author_facet Bidzińska, Joanna
Szurowska, Edyta
author_sort Bidzińska, Joanna
collection PubMed
description SIMPLE SUMMARY: Lung cancer is the cause of many deaths that could have been avoided if the disease had been detected at an early stage. This is possible thanks to the lung cancer screening (LCS) program with the low-dose computed tomography (LDCT) of the chest. Due to the heavy workload on the healthcare system, shortages of specialists, and expensive equipment, new solutions are needed to support the work of the hospitals. One of the most promising is the use of artificial intelligence (AI). In this paper, we present promising results and discuss whether/why AI application in medicine, with an emphasis on lung cancer, is needed. It is speculated that thanks to an innovative AI solution many lives could be saved. ABSTRACT: A lot has happened in the field of lung cancer screening in recent months. The ongoing discussion and documentation published by the scientific community and policymakers are of great importance to the entire European community and perhaps beyond. Lung cancer is the main worldwide killer. Low-dose computed tomography-based screening, together with smoking cessation, is the only tool to fight lung cancer, as it has already been proven in the United States of America but also European randomized controlled trials. Screening requires a lot of well-organized specialized work, but it can be supported by artificial intelligence (AI). Here we discuss whether and how to use AI for patients, radiologists, pulmonologists, thoracic surgeons, and all hospital staff supporting screening process benefits.
format Online
Article
Text
id pubmed-9954317
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99543172023-02-25 See Lung Cancer with an AI Bidzińska, Joanna Szurowska, Edyta Cancers (Basel) Review SIMPLE SUMMARY: Lung cancer is the cause of many deaths that could have been avoided if the disease had been detected at an early stage. This is possible thanks to the lung cancer screening (LCS) program with the low-dose computed tomography (LDCT) of the chest. Due to the heavy workload on the healthcare system, shortages of specialists, and expensive equipment, new solutions are needed to support the work of the hospitals. One of the most promising is the use of artificial intelligence (AI). In this paper, we present promising results and discuss whether/why AI application in medicine, with an emphasis on lung cancer, is needed. It is speculated that thanks to an innovative AI solution many lives could be saved. ABSTRACT: A lot has happened in the field of lung cancer screening in recent months. The ongoing discussion and documentation published by the scientific community and policymakers are of great importance to the entire European community and perhaps beyond. Lung cancer is the main worldwide killer. Low-dose computed tomography-based screening, together with smoking cessation, is the only tool to fight lung cancer, as it has already been proven in the United States of America but also European randomized controlled trials. Screening requires a lot of well-organized specialized work, but it can be supported by artificial intelligence (AI). Here we discuss whether and how to use AI for patients, radiologists, pulmonologists, thoracic surgeons, and all hospital staff supporting screening process benefits. MDPI 2023-02-19 /pmc/articles/PMC9954317/ /pubmed/36831662 http://dx.doi.org/10.3390/cancers15041321 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bidzińska, Joanna
Szurowska, Edyta
See Lung Cancer with an AI
title See Lung Cancer with an AI
title_full See Lung Cancer with an AI
title_fullStr See Lung Cancer with an AI
title_full_unstemmed See Lung Cancer with an AI
title_short See Lung Cancer with an AI
title_sort see lung cancer with an ai
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954317/
https://www.ncbi.nlm.nih.gov/pubmed/36831662
http://dx.doi.org/10.3390/cancers15041321
work_keys_str_mv AT bidzinskajoanna seelungcancerwithanai
AT szurowskaedyta seelungcancerwithanai